Compare ZGN & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZGN | WVE |
|---|---|---|
| Founded | 1910 | 2012 |
| Country | Italy | Singapore |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.4B |
| IPO Year | 2021 | 2015 |
| Metric | ZGN | WVE |
|---|---|---|
| Price | $13.30 | $6.35 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 16 |
| Target Price | $11.28 | ★ $29.81 |
| AVG Volume (30 Days) | 747.8K | ★ 4.2M |
| Earning Date | 03-20-2026 | 04-28-2026 |
| Dividend Yield | ★ 1.22% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,704,000.00 |
| Revenue This Year | $5.17 | N/A |
| Revenue Next Year | $7.89 | $85.67 |
| P/E Ratio | $25.94 | ★ N/A |
| Revenue Growth | N/A | ★ 149.43 |
| 52 Week Low | $7.61 | $5.02 |
| 52 Week High | $13.50 | $21.73 |
| Indicator | ZGN | WVE |
|---|---|---|
| Relative Strength Index (RSI) | 63.96 | 34.87 |
| Support Level | $9.89 | $5.02 |
| Resistance Level | $13.38 | $7.65 |
| Average True Range (ATR) | 0.44 | 0.38 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 88.69 | 19.12 |
Ermenegildo Zegna NV designs creates, and distributes luxury menswear and accessories under the Zegna brand, as well as womenswear, menswear, and accessories under the Thom Browne brand. The company operates in three segments: the Zegna segment (comprising three product lines: Zegna Branded Products, Textile, and Third Party Brands); the Thom Browne segment, and the Tom Ford Fashion segment. The company generates the majority of its revenue from the Zegna segment.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.